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ORIGINAL ARTICLE
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Rejuvenation? Evaluation of Effects of Platelet-rich 
Plasma on Human Dermal Fibroblast
Dae Hun Kim, M.D., Young Jin Je, M.S., Chang Deok Kim, Ph.D., Young Ho Lee, M.D.
1, 
Young Joon Seo, M.D., Jeung Hoon Lee, M.D., Young Lee, M.D.
Departments of Dermatology and 
1Anatomy, College of Medicine, Chungnam National University, Daejeon, Korea
Background: Autologous platelet-rich plasma has attracted 
attention in various medical fields recently, including 
orthopedic, plastic, and dental surgeries and dermatology for 
its wound healing ability. Further, it has been used clinically 
in mesotherapy for skin rejuvenation. Objective: In this 
study, the effects of activated platelet-rich plasma (aPRP) and 
activated platelet-poor plasma (aPPP) have been investigated 
on the remodelling of the extracellular matrix, a process that 
requires activation of dermal fibroblasts, which is essential 
for rejuvenation of aged skin. Methods: Platelet-rich plasma 
(PRP) and platelet-poor plasma (PPP) were prepared using a 
double-spin method and then activated with thrombin and 
calcium chloride. The proliferative effects of aPRP and aPPP 
were measured by [
3H]thymidine incorporation assay, and 
their effects on matrix protein synthesis were assessed by 
quantifying levels of procollagen type I carboxy-terminal 
peptide (PIP) by enzyme-linked immunosorbent assay (ELISA). 
The production of collagen and matrix metalloproteinases 
(MMP) was studied by Western blotting and reverse 
transcriptase-polymerase chain reaction. Results:  Platelet 
numbers in PRP increased to 9.4-fold over baseline values. 
aPRP and aPPP both stimulated cell proliferation, with peak 
proliferation occurring in cells grown in 5% aPRP. Levels of 
PIP were highest in cells grown in the presence of 5% aPRP. 
Additionally, aPRP and aPPP increased the expression of 
type I collagen, MMP-1 protein, and mRNA in human dermal 
fibroblasts.  Conclusion: aPRP and aPPP promote tissue 
remodelling in aged skin and may be used as adjuvant 
treatment to lasers for skin rejuvenation in cosmetic 
dermatology. (Ann Dermatol 23(4) 424∼431, 2011)
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INTRODUCTION
Platelet-rich plasma (PRP) is an autologous preparation of 
platelets in concentrated plasma. Although the optimal 
PRP platelet concentration is unclear, the current methods 
by which PRP is prepared is reported to involve 300∼
700% enrichment, with platelet concentrations conse-
quently increasing to greater than 1,000,000 platelets/μl
1,2.
Various growth factors, including platelet-derived growth 
factor (PDGF), transforming growth factor (TGF), vascular 
endothelial growth factor (VEGF), and insulin-like growth 
factor (IGF), are secreted from the α-granules of concen-
trated platelets activated by aggregation inducers
3. These 
factors are known to regulate processes including cell mi-
gration, attachment, proliferation and differentiation, and 
promote extracellular matrix (ECM) accumulation by bind-
ing to specific cell surface receptors
4,5.
Due to the presence of high concentrations of these 
growth factors, PRP has been used in a wide variety of 
surgical procedures and clinical treatments, including the 
treatment of problematic wounds
6 and maxillofacial bone Effects of Platelet-rich Plasma on Fibroblast
Vol. 23, No. 4, 2011 425
defects
7, cosmetic surgeries
8,9, and gastrointestinal sur-
geries
10. Recently, PRP has attracted attention in the field 
of dermatology, specifically in the aesthetic field for skin 
rejuvenation.
Aging of human skin results from a combination of a 
gradual decline in function over time (intrinsic aging) and 
cumulative damage caused by environmental factors 
(extrinsic aging), which include smoking, exposure to 
chemicals, and notably, ultraviolet B (UVB) radiation. In 
dermis, UVB has shown to stimulate collagenase pro-
duction by human dermal fibroblasts (HDF) and induce 
collagenase gene expression
11-14. In skin, which is con-
tinually exposed to UVB, collagen degeneration and al-
tered deposition of elastic tissue result in the impairment 
of the structural integrity of the dermal ECM causing the 
skin to wrinkle. The skin’s resilience is also reduced.
Topical application of growth factors stimulates the re-
juvenation of photoaged facial skin, improving its clinical 
appearance and inducing new collagen synthesis
15,16. 
Since PRP secretes various growth factors with roles in 
skin regeneration, it may be hypothesized that PRP may 
induce the synthesis of collagen and other matrix com-
ponents by stimulating the activation of fibroblasts, thus, 
rejuvenating the skin. Though PRP is widely used in 
clinical dermatology, experimental studies confirming the 
effects of PRP on aged fibroblasts are very limited.
The aim of this study was to evaluate the effects of PRP on 
fibroblast function in vitro and remodelling of ECM com-
ponents in a manner that can contribute to rejuvenation of 
skin, and further to generate data relevant to the potential 
clinical application of PRP as an anti-aging therapy.
MATERIALS AND METHODS
Fibroblast isolation and culture
Normal human skin samples were obtained from cir-
cumcisions, in accordance with the ethical committee 
approval process of Chungnam National University Hos-
pital. Specimens were briefly sterilized in 70% ethanol, 
minced, and incubated in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and antibiotics. Dermal fibroblasts normally 
outgrew from the explants after 5∼7 days. At 
confluence, cells were routinely passaged using a 1:4 
split ratio. Cells were starved of serum for 24 h, then 
treated with activated PRP (aPRP) and activated PPP 
(aPPP), in serum-free medium.
Preparation of PRP and PPP
PRP and PPP were prepared using a double-spin method 
as described in a previous study
16. In brief, blood was ob-
tained from healthy adult volunteers (n=10) after receiv-
ing informed consent and collected into tubes containing 
acid-citrate-dextrose solution formula A (1：4 vol/vol) 
anticoagulant. The citrated blood was centrifuged in a 
standard laboratory centrifuge for 7 min at 3,000 rpm. 
Subsequently, the yellow plasma (containing buffy coat 
with platelets and leukocytes) was taken up using a 
micropipette. A second round of centrifugation was per-
formed for 5 min at 4,000 rpm. The pellet containing pla-
telets accumulated at the bottom and the platelet-poor 
plasma surfaced to the top. The plasma supernatant was 
used as PPP and the thrombocyte pellet in 1.0 ml of plas-
ma was used as PRP. A 1：1 (vol/vol) mixture of 0.5 M 
calcium chloride and thrombin was prepared in advance 
as an activator. A 10：1 (vol/vol) mixture of PRP or PPP 
and activator was incubated for 10 min at room temper-
ature, and this mixture was regarded as aPRP or aPPP. 
aPRP and aPPP were centrifuged at 13,000 rpm for 15 
minutes. The supernatant was stored at −20
oC until used.
Fibroblast proliferation assay
Dermal fibroblasts were seeded at a density of 1×10
4 
cells/well in six-well culture plates. After starvation for 24 h, 
the cells were cultured in serum-free DMEM supplemented 
with 0% (control), 5%, 10% aPRP or aPPP for 3 and 5 
days. In parallel, the cells were cultured in DMEM sup-
plemented with 5% FBS as positive control. To measure 
the proliferative potential of cells, [
3H]thymidine incor-
poration assay was carried out as previously reported
17. 
Cells were grown in six-well plates for 48 h, then 
incubated with 1μCi of [
3H]thymidine for the indicated 
time points. After incubation, cells were washed twice 
with cold phosphate buffered saline (PBS), then dissolved 
in 0.2 M NaOH for 30 min. Lysates were then mixed with 
scintillation cocktail and the incorporated [
3H]thymidine 
level was measured by liquid scintillation counting 
(Beckman, Mountain View, CA, USA).
Procollagen type I carboxy-terminal peptide production
Cells (1×10
5) were seeded in a six-well culture plate and 
grown to confluence in DMEM supplemented with 10% 
FBS. Cells were starved of serum for 24 h, then further 
cultured in 3 ml of fresh serum-free DMEM with aPRP and 
aPPP at the indicated concentrations for 2 days. The level 
of Procollagen type I carboxy-terminal peptide (PIP) in the 
conditioned media was quantified using an ELISA kit 
(Takara Bio Inc., Shiga, Japan) according to the manu-
facturer’s recommended protocol. The detection limit of 
the assays was 10 ng/ml. Measurements were taken at 
least three times.DH Kim, et al
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Fig. 2. aPPP and aPRP treatment increased the proliferation of cultured fibroblast. After serum-starvation for 24 h, fibroblasts were
cultured with FBS, aPPP, or aPRP at concentrations as indicated. [
3H]thymidine incorporation was measured at 3 and 5 days after
the addition of various concentrations of aPRP and aPPP to the growth medium. (A) HDF proliferation on day 3 after control (serum-free
medium), 5% FBS, aPPP, and aPRP additions. (B) HDF proliferation on day 5 after control (serum-free medium), 5% FBS, aPPP, and
aPRP additions. *p＜0.05  vs. control, 
†p＜0.05  vs. 5% FBS (positive control). Con: control (serum-free medium), aPPP: activated
platelet-poor plasma, aPRP: activated platelet-rich plasma, HDF: human dermal fibroblasts, FBS: fetal bovine serum.
Fig. 1. Platelet concentrations after double-spin method (n=5). (A)
Microscopic examination of stained platelet smears (×40). (B) 
Quantified platelet counts indicate increased number of platelets
in platelet-rich plasma. *p＜0.05 vs. Control. nPPP: non-activated
platelet-poor plasma, nPRP: non-activated platelet-rich plasma.
Reverse transcriptase-polymerase chain reaction (RT- 
PCR)
RT-PCR was performed using an RNA PCR kit (Intron Inc. 
Seongnam, Korea) according to the manufacturer’s instruc-
tions. To summarize, 2μg of the total RNA were reverse 
transcribed using oligo (dT) primer. Aliquots of ReT mix-
ture were subjected to PCR cycles with specific primer 
sets for type I collagen alpha 1 (COL1A1) (5'-CCTTTCTGC 
TCCTTTCTCCA and 5'-AGCAACACAGTTvACACAAGG), 
type I collagen alpha2 (COL1A2) (5'-CCCTTGTTACCG 
CTCTCTOC and 5'- CCGTTGGACCTCCTGG TAAT), PCR Effects of Platelet-rich Plasma on Fibroblast
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Fig. 3. Procollagen type I carboxy-terminal peptide (PIP) 
production in aPRP and aPPP treated human dermal fibroblasts. 
After 24 h of serum-starvation, cells were cultured in serum-free
(Con), 5% FBS or 1, 5, or 10% aPRP or aPPP treated culture 
medium for 48 h. PIP was quantified using an ELISA kit. *p
＜0.05  vs. control, Con: control (serum-free medium), aPPP: 
activated platelet-poor plasma, aPRP: activated platelet-rich
plasma, FBS: fetal bovine serum.
fragments were electrophoresed on 1.0% agarose gels and 
subsequently visualized by ethidium bromide staining.
Immunoblotting
Cells (1×10
6) were seeded on 100-mm culture dishes and 
grown to confluence. Cells were starved of serum for 24 
h, then treated with aPRP and aPPP in serum-free medium 
for 2 days. Cell extracts were prepared in lysis buffer con-
taining 62.5 mM Tris, pH 6.8, 50 mM DTT, 2% SDS, 10% 
glycerol, and proteinase inhibitors. Total protein was 
measured using a Bradford protein assay kit (Bio-Rad 
Laboratories, Hercules, CA, USA). Samples were run on 
10% SDS-polyacrylamide gels, transferred onto nitro-
cellulose membranes, and incubated with anti-COL1 1 
and COL1 2 antibodies or anti-MMP-1 and anti-MMP-3 
antibodies at a dilution of 1：1,000 in 5% skim milk in 
TBS-T (Tris Buffered Saline Tween, 25 mM Tris, 150 mM 
NaCl, 0.05% Tween 20, pH=8.0). Blots were then 
incubated with peroxidase-conjugated secondary at a 
dilution of 1：2,000 in 5% skim milk in TBS-T, and were 
developed by enhanced chemiluminescence (Amersham, 
Buckinghamshire, UK).
Statistical analysis
Statistical analysis was performed with the SPSS ver. 12.0 
(SPSS Inc., Chicago, IL, USA) for Windows. The t-test and 
parametric analysis of variance (ANOVA) with Scheffe’s 
post-hoc multiple comparison tests were used for 
comparison between groups with values of p＜0.05 being 
regarded as significant. Data are presented as mean±SD. 
RESULTS
Concentration of platelets in PRP and PPP
PRP and PPP smears were stained with Wright-Giemsa- 
solution. Subsequent microscopic examinations indicated that 
PRP has a higher platelet concentration than PPP (Fig. 1A). 
Mean platelet counts in whole blood, PRP, and PPP were 
1.8×10
5, 1.7×10
6, and 3.1×10
4 cells/μl, respectively. 
The concentration of platelets in PRP was approximately 
9.4-fold greater than in whole blood (Fig. 1B).
aPRP and aPPP treatment increased the proliferation in 
human dermal fibroblasts
Compared to the serum-treated control group, aPRP and 
aPPP showed marked increase in fibroblast proliferation. 
Proliferation of cells grown in medium supplemented with 
5% aPRP peaked on day five (Fig. 2). Cells exposed to 5 
or 10% aPRP also exhibited significantly higher rates of 
proliferation than positive control cells (grown in medium 
supplemented with 5% FBS). These results indicate that 
aPRP and aPPP promote the proliferation of fibroblasts, 
with 5% aPRP producing maximal stimulation of proli-
feration.
aPRP and PPP increased production of procollagen 
type I carboxy-terminal peptide by human dermal 
fibroblasts
To investigate whether aPPP or aPRP regulates collagen 
production in cultured HDF, the PIP production was 
examined, which indirectly reflects overall collagen I 
levels. Levels of PIP showed maximum increase in cells 
cultured in a medium treated with 5% aPRP (Fig. 3). 
While aPPP increased PIP levels dose-dependently, 5% 
aPRP tended to induce the production of PIP more 
strongly than 10% aPRP. The data was consistent with the 
fibroblast pcroliferation assay, where the fibroblast proli-
feration was maximum in 5% aPRP. aPRP and aPPP both 
increased PIP production relative to the control, aPRP 
more potently than aPPP.
aPRP and aPPP increased the expression of collagen 
type I, alpha1 andollagen type I, alpha2
The effects of aPPP or aPRP were investigated on the 
expression of type I collagen mRNA and protein in 
cultured HDF. Type I collagen is the most abundant 
collagen component of the dermis and is assembled with 
pro-alpha collagen chains encoded by collagen type I 
alpha 1 (COL1A1), which is the major component of type 
Icollagen, and collagen type I alpha 2 (COL1A2). 
COL1A1 and COL1A2 mRNA and prot ein expression 
were quantified by RT-PCR and western blotting after 48 h DH Kim, et al
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Fig. 4. aPRP and aPPP treatment in culture medium increased the expression of collagen type I, alpha1 and collagen type I, alpha2 
mRNA and protein expression in cultured human dermal fibroblasts. After 24 h of serum-starvation, cells were cultured in serum-free 
(Con), 5% FBS, 5% aPRP, or aPPP treated culture medium for 48 h. α1 chains of type I collagen mRNA and protein expression 
were determined by (A) RT-PCR, (B) western blotting, respectively. (C) α2 chains of type I collagen mRNA expression was determined
by RT-PCR, (D) western blotting. *p＜0.05 vs. control, 
†p＜0.05 vs. 5% FBS (positive control). Con: control (serum-free medium), 
aPPP: activated platelet-poor plasma, aPRP: activated platelet-rich plasma, RT-PCR: reverse transcriptase-polymerase chain reaction, 
FBS: fetal bovine serum.
incubation with 5% aPRP or aPPP. Both, aPRP and aPPP 
stimulated the mRNA expression of the pro-alpha 1(I) and 
pro-alpha 2(I) chains of type I collagen more significantly 
than the serum-free treated control (Fig. 4A and C). 
The protein expression of the COL1A1 and COL1A2 of 
type I collagen was significantly higher in the aPRP or Effects of Platelet-rich Plasma on Fibroblast
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Fig. 5. aPRP and aPPP treatment in culture medium increased the expression of MMP-1 and MMP-3 protein expression in cultured
HDF. (A) After 24 h of serum-starvation, cells were cultured in serum-free (Con), 5% FBS, 5% aPRP, or aPPP treated culture medium
for 48 h. MMP-1 protein expression was detected by western blotting. (B) After 24 h of serum-starvation, cells were cultured in serum-free
(Con), 5% FBS, 5% aPRP, or aPPP treated culture medium for 48 h. MMP-3 protein expression was detected by western blotting. 
*p＜0.05 vs. control, 
†p＜0.05 vs. 5% FBS (positive control). Con: control (serum-free medium), aPPP: activated platelet-poor plasma,
aPRP: activated platelet-rich plasma, MMP: matrix metalloproteinases, HDF: human dermal fibroblasts, FBS: fetal bovine serum.
aPPP treated dermal fibroblasts than the serum-free 
(control) treated sample (Fig. 4B and D). Though the 
expression of COL1A1 and COL1A2 protein were highest 
in dermal fibroblasts treated with 5%  FBS (positive con-
trol), there was no statistical significance. 
aPRP and aPPP increased expression of MMP-1 and 
MMP-3 protein 
We examined the effects of aPPP or aPRP on MMP-1 and 
MMP-3 protein expression in cultured HDF. The 
fibroblasts were cultured in serum-free media for 24 h and 
then treated with either 5% FBS, aPPP, or aPRP. The cells 
were harvested after 48 h to measure the protein ex-
pression. Both aPPP and aPRP increased the expression of 
MMP-1 and MMP-3 proteins in HDF. The production of 
MMP-1 protein was highest in 5% aPRP treated fibroblasts 
(Fig. 5A). MMP-3 protein levels were significantly higher 
in 5% aPPP than in the serum-free treated fibroblast, but 
there was no statistical significance between 5% aPPP and 
5% aPRP treated fibroblasts (Fig. 5B).
DISCUSSION
Dermal fibroblasts play a key role in the aging processes 
through their interactions with keratinocytes, adipocytes, 
and mast cells. They are also the source of ECM proteins, 
glycoproteins, adhesive molecules, and various cyto-
kines
18. By producing these molecules and supporting cell 
to cell interactions, skin fibroblasts contribute to the 
fibroblast-keratinocyte-endothelium axis that maintains 
skin integrity and youthfulness
19. Conventional anti-aging 
strategies, such as those involving lasers and topical 
treatments, typically aim to increase ECM synthesis 
through the activation of fibroblasts. PRP is widely applied 
in many clinical fields of surgery for its ability to stimulate 
wound healing and minimize bleeding during surgery. 
Recently, PRP has drawn the attention of dermatologists 
for its various growth factors in the α-granules, including 
PDGF, TGF, VEGF, and IGF, ability to stimulate HDF, and 
treat skin wrinkles and rejuvenate the skin. However, little 
is known about the effects of PRP and PPP on ECM 
remodelling or fibroblast activation.
PRP and PPP were prepared by the manual separation of 
blood cell layers using a double-spin method. The acti-
vation of platelets through coagulation triggers the secre-
tion of various growth factors, which produce mitogenic 
effects in various cell types
20-28. The proliferation of osteo-
blasts
26 and alveolar bone cells
27 treated with 1∼5% PRP DH Kim, et al
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was higher than that of cells treated with higher con-
centrations of PRP. Similarly, it was shown that maximal 
stimulation of HDF proliferation was achieved using 5% 
aPRP
29. Our study indicates that aPRP stimulates the 
proliferation of HDF, consistent with the findings des-
cribed above. Additionally, we confirmed that 5% (vol/vol) 
was a suitable concentration of aPRP for the treatment of 
HDF in vitro.
PIP production, which reflects overall collagen levels, was 
also highest in cells treated with 5% aPRP, the same 
concentration of PRP that induced maximum cellular 
proliferation. On the other hand, the expression of the α1 
and α2 chains of type I collagen was increased in cells 
treated with 5% aPRP or aPPP (compared with negative 
control), as assessed by Western blotting. Similar in-
duction of COL1A1 and COL1A2 mRNA expression was 
detected by RT-PCR, suggesting that PRP and PPP both 
showed an ability to induce collagen production by HDF. 
The reason for aPRP not showing superior efficacy on 
collagen production compared to aPPP is not known, but 
there could be several hypotheses to explain the reason. 
First, the platelets could secrete various growth factors 
from the α-granule without the activation of platelets with 
calcium and thrombin during the process of creating PRP. 
Second, although several growth factors are secreted from 
the platelets, its effect on the production of collagen from 
HDF is minimal and there is no difference among aPPP, 
aPRP, and serum in the production of collagen. Third, 
since aPPP showed increased PIP and collagen production 
in HDF, there may be other factors in the plasma that 
stimulate collagen production other than growth factors 
secreted from α-granules of platelets. None of the hy-
potheses could be proved in this study, but more 
investigative studies need to be done to confirm the 
factors stimulating the collagen production in PRP and 
PPP. This stimulation of de novo collagen synthesis may 
compensate for the defects that arise due to the frag-
mentation or loss of collagen in photoaged and aged skin. 
Accumulation of this newly-synthesized collagen may 
improve the structural integrity of the dermal ECM and 
stimulate fibroblasts to produce more collagen
29.
aPRP and aPPP showed an increase in the expression of 
MMP-1 and MMP-3 protein. MMPs digesting various st-
ructural components of the ECM are centrally involved in 
dermal remodelling
30. Similar induction of MMP-1 in 
photoaged skin may facilitate the removal of collagen 
fragments that damage the dermal matrix tissue, thus 
providing a better foundation for the deposition of new 
collagen
29.
aPRP may induce ECM remodelling by stimulating the 
removal of photodamaged ECM components and inducing 
the synthesis of new collagen by fibroblasts, which are in 
turn proliferated by their stimulation. In recent studies, 
injection of PRP in the face and neck for revitalization 
obtained good results
30. However, there is yet no clearly 
defined method for the clinical application of PRP. 
Methods being tested include topical application or direct 
injection into the skin. Strategies for increasing skin 
remodelling by increasing penetration and inducing mild 
inflammatory reactions, include the use of microneedles 
and lasers. However, the anti-aging effects of these plasma 
treatments in vivo remain to be determined. Additional 
studies are required to determine whether such approa-
ches produce beneficial effects in aged skin.
To summarize, the stimulation of dermal fibroblast 
proliferation by aPRP was demonstrated in this study. 
aPPP and aPRP increased type I collagen and MMPs gene 
expression, suggesting that aPRP and aPPP may have the 
potential to promote the remodelling of aged and 
photoaged skin. Considering limited studies on clinical 
efficacy and safety, further studies are required to inves-
tigate the mechanism and safety on autologous blood-
derived PRP and PPP before clinical application.  
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